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LETTER TO THE EDITOR
Low Antibiotic Resistance of Helicobacter pylori in The
Netherlands
To the Editor,
Consensus guidelines on treatment of Helicobacter
pylori (H. pylori) in adults as well as in children recom-
mend in areas with prevalence of clarithromycin resis-
tance <15–20%, 7–10 days triple therapy with
amoxicillin, clarithromycin or metronidazole and a pro-
ton-pump inhibitor (PPI), and alternative eradication
regimens if the resistance rate is higher [1,2]. With this
regimen, eradication rates vary from 60 to 90%. How-
ever, the success rate of standard triple therapy for
H. pylori eradication is decreasing worldwide due to
increasing antimicrobial resistance of H. pylori to clari-
thromycin and/or metronidazole, probably because of
the increasing use of clarithromycin for respiratory
infections (especially in children) and the use of metro-
nidazole for parasitic infections. Alternative regimens
containing tetracyclines or bismuth are not allowed in
children in many countries. Currently, sequential ther-
apy is a topic of research in adults as well as in children
to improve the eradication rate.
Dutch guidelines recommend test-and-treat, which
is safe and as effective as direct endoscopy, in the
absence of alarm symptoms in persons <45 years of age
[3]. However, data on resistance of H. pylori isolated
from adults are only available until 2003, [4] and resis-
tance in children has never been investigated.
In order to estimate whether the test-and-treat
approach is justified in the Netherlands, we analyzed
the prevalence of resistance to clarithromycin and met-
ronidazole in H. pylori -positive cultures from biopsies
from the gastric antrum and/or corpus of adults and
children (<18 years of age) from January 2000 to
December 2009. For most adult patients, it was
unknown whether or not they had undergone nonin-
vasive testing before and whether or not they had been
treated before. None of the children had been treated
for H. pylori before the first endoscopy. Cultures of
biopsies for H. pylori were carried out, and H. pylori pos-
itivity was determined with a Gram stain and a positive
oxidase, catalase, and urease test. Strains were consid-
ered clarithromycin sensitive if MIC ≤ 0.25, metronida-
zole sensitive if MIC ≤ 8 mg/L, intermediate if MIC > 8
and MIC ≤ 16 mg/L, and resistant if MIC > 16 mg/L,
according to the Eucast-criteria (www.eucast.org).
Demographic data and results of resistance to antibi-
otics are summarized in Table 1. From 1152 patients,
1214 cultures were positive for H. pylori. Susceptibility
of clarithromycin and metronidazole could be deter-
mined in 1088 (90%) and 1095 (90%) cultures, respec-
tively. All clarithromycin-resistant strains in children
were detected in the period after 2004, while metroni-
dazole-resistant strains were divided equally over the
whole period. During the study period, the resistance to
clarithromycin increased from <5 to 8.5–9.4% in adults
and resistance to metronidazole increased from 7–33 to
20.7–22.9%.
In second occasion biopsies, H. pylori from 4 of 41
cultures from adults became resistant to clarithromycin
and 4 to metronidazole. In third occasion biopsies, 1
and 2 strains from adults became resistant to clarithro-
mycin and metronidazole, respectively.
Table 1 Demographic data and results
Parameters Adults (N = 1080) Children (N = 72)
Males (N) 510 42








Resistance to Cla, % of
tested strains
9.4 7.2









Cla and MNZ (%)
2.8 0
R, resistant; S, sensitive; I, intermediate; NT, not tested due to viability
problems of the strains; Cla, Clarithromycin; MNZ, Metronidazole.
aPercentage of isolates.
© 2014 John Wiley & Sons Ltd, Helicobacter 20: 69–70 69
Helicobacter ISSN 1523-5378
doi: 10.1111/hel.12175
The resistance rate to clarithromycin is low com-
pared with other European countries, where the preva-
lence in adults has been reported from 17–26% up to
68% in case of secondary resistance. The most likely
explanation is the restrictive policy for antibiotic pre-
scriptions by Dutch physicians [5]. The prescription of
clarithromycin has stabilized since 2003 (www.swab/
nethmap.nl) in contrast to the prescription pattern in
other European countries. In adults, H. pylori resistance
to metronidazole has increased, [4] but it is still lower
than reported from other European countries (27–
61%). Double resistance to clarithromycin and metroni-
dazole occurred in 2.8% of the strains and remained
stable over time.
This study is the first to report data on the anti-
microbial resistance of H. pylori in children living in
the Netherlands and shows much lower resistance
rates of H. pylori strains than those reported in other
parts of Europe (24 and 25% to clarithromycin and
metronidazole, respectively [6]). In the European
study, 41% of the children with resistant strains were
offspring of non-European mothers, in contrast to
11% of the children with resistant strains from non-
Dutch mothers.
The low resistance rates to clarithromycin and met-
ronidazole are remarkable, in view of the implementa-
tion of the stool antigen test in 2000 and subsequent
gradual introduction of the test-and-treat regimen,
without previous determination of H. pylori susceptibil-
ity. With such approach, one would have expected
higher secondary resistance rates, as the endoscopic
samples were probably more often from patients who
failed first line therapy.
In summary, the low antibiotic resistance rate of
H. pylori strains in Dutch adults and in children sup-
ports the recommendation to routinely perform a test-
and-treat regimen in the Netherlands. Also in the com-
ing years, surveillance of regional H. pylori resistance is
needed to timely modify treatment regimens. It is
hoped that future development of noninvasive suscepti-
bility tests for clarithromycin in stool samples will facili-
tate this procedure.
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